ADPT vs ARGX
Adaptive Biotechnologies Corporation vs argenx SE — AI-powered side-by-side comparison
ADPT
Adaptive Biotechnologies Corporation
59
Watch
VS
| Metric | ADPT | ARGX |
|---|
| AI Score |
59
|
69
|
| Price |
$25.39
|
$864.40
|
| P/E Ratio |
-62.32×
|
31.34×
|
| ROE |
-27.2%
|
17.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
89.9%
|
| Debt / Equity |
2.87×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
67.3
|
47.9
|
| Beta |
2.088
|
-0.022
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ADPT versus ARGX.
ARGX leads by 10 points.
ARGX scores 69/100 (Buy) versus ADPT at 59/100 (Watch).
ADPT Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 11.3x prices in significant intangible value — Value
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical